ARTV Projected Dividend Yield
Artiva Biotherapeutics Inc ( NASDAQ : ARTV )Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Co.'s product candidates are derived from donor cells and pre-manufactured, stored frozen and ship to a patient's treatment location. Co.'s lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. 21 YEAR PERFORMANCE RESULTS |
ARTV Dividend History Detail ARTV Dividend News ARTV Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |